Clinical trials: leukemia
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.
- Trial name
- NCT00659425
- Testing
- CAT-8015 (Moxetumomab Pasudotox)
- Where
- 5 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- MedImmune LLC
Leukemia, Myeloid, Acute
Post-transplant Flotetuzumab for AML
The purpose of this research study is to determine if the study drug, flotetuzumab, is safe and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed after transplant.
- Trial name
- NCT05506956
- Testing
- Flotetuzumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Acute Myeloid Leukemia (AML)
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) following induction chemotherapy. However, a large majority subsequently relapse and succumb to the disease.
- Trial name
- NCT02927938
- Testing
- Allogeneic HCT, Consolidation chemotherapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia
RN-Led Palliative and Supportive Care Intervention
This single institution feasibility and acceptability study includes patients with acute leukemia which is designed to examine a novel palliative and supportive care intervention (Palliative and supportive Care inTervention…
- Trial name
- NCT04570709
- Testing
- Palliative And supportive Care inTervention (PACT)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
The purpose of this randomized, two-arm, open-label expansion phase study was to collect preliminary efficacy data of panobinostat at the recommended phase II dose (RPIID) level in combination with azacytidine (5-Aza) versus an…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT00946647
- Testing
- Panobinostat (LBH589), 5-Azacytidine
- Where
- 38 sites in United States, Austria and 12 more
- Volunteers
- 113 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
The study is designed as a phase III, randomized, open label, multicenter, prospective, comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis after human…
- Conditions
- Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
- Trial name
- NCT00406393
- Testing
- Tacrolimus, Methotrexate, Sirolimus
- Where
- 24 sites in United States, France
- Volunteers
- 304 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
The objective is to treat elderly AML and MDS patients with sapacitabine.
- Trial name
- NCT00590187
- Testing
- Sapacitabine, Arm A, Sapacitabine, Arm B, Sapacitabine, Arm C
- Where
- 15 sites in United States
- Volunteers
- 105 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Perifosine inhibits the AKT pathway (a way cells communicate with each other). This pathway is felt to be important in the development of several types of cancers including chronic lymphocytic leukemia (CLL) or small lymphocytic…
- Trial name
- NCT00873457
- Testing
- perifosine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Daphne Friedman
Myelodysplastic Syndromes
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
The primary purpose of this research study is to assess whether the participant's disease, Myelodysplastic Syndromes (MDS), responds favorably to INCB024360.
- Trial name
- NCT01822691
- Testing
- INCB024360
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing.
- Conditions
- Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00602225
- Testing
- clofarabine, cytarabine, filgrastim
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Trial name
- NCT01929408
- Where
- 12 sites in United States
- Volunteers
- 703 people
- Sponsor
- Fred Hutchinson Cancer Center
Plasma Cell Leukemia, Plasmacytoma
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or…
- Conditions
- Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT02506959
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH…
- Trial name
- NCT04764474
- Testing
- HMPL-306
- Where
- 15 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- Hutchmed
Solid Tumor Malignancy, Hematologic Malignancy
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Background: Coronavirus disease (COVID-19) is a viral infection. It has spread rapidly across the globe. It has overwhelmed health systems.
- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma
- Trial name
- NCT04847050
- Testing
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelocytic, Acute
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients…
- Trial name
- NCT01339910
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 32 sites in United States
- Volunteers
- 272 people
- Sponsor
- Medical College of Wisconsin
Leukemia
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of…
- Trial name
- NCT00469859
- Testing
- cytarabine, idarubicin, lestaurtinib
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Children's Oncology Group
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
This research study is evaluating a combination of drugs called Ofatumumab and Idelalisib as a possible treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL).
- Trial name
- NCT02135133
- Testing
- Idelalisib, Ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
This randomized pilot early phase I trial studies how well cholecalciferol works in treating patients with newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia with low levels of vitamin D (vitamin D deficiency).
- Conditions
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Untreated Chronic Lymphocytic Leukemia, Vitamin D Deficiency
- Trial name
- NCT02553447
- Testing
- Cholecalciferol, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- University of Nebraska
Lymphoma
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00244985
- Testing
- rituximab, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.